Author Affiliations: Provider Resources Inc (Dr Cook) and Lake Erie College of Osteopathic Medicine School of Pharmacy (Dr Powers), Erie, Pennsylvania.
We commend Dr Woo for highlighting additional processes used by the US Food and Drug Administration (FDA) to monitor and disseminate postmarketing drug safety information in accordance with the Food and Drug Administration Amendments Act. Also, we commend the commentaries of Wolf1 and Dal Pan and Temple.2 They highlight the importance of our study3 along with the importance of potential signals of serious risks identified through the Adverse Event Reporting System (AERS). We echo the concerns of Dal Pan and Temple,2 as there may be no easy solution for identified potential safety signals since evidence of a true signal is limited. Despite the limited evidence of a true signal, we firmly believe that health care professionals and the public should continue to monitor these reports from the FDA and choose alternative therapies when applicable if serious potential risks are present. Overall, we are in support of the comments by Wolf.1
Cook GE, Powers A. Potential Safety Signals and Their Significance—Reply. Arch Intern Med. 2012;172(9):747–748. doi:10.1001/archinternmed.2012.1297
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: